Recently unearthed emails, letters to regulators and legal strategy documents sent by Allergan, Inc. (NYSE:AGN) executives and their consortium of paid consultants paint a picture of a company engaged in a multiple-prong attack to damage the reputation of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX), sink its stock price and fight a regulatory battle.
Allergan's attempt to manipulate the stock price of Valeant Pharmaceuticals
Perhaps most interesting about the 30 some documents reviewed by ValueWalk, many marked “confidential” or “highly confidential,” are what appear to be direct attempts to manipulate the stock price of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX). The documents...